10:23 AM
 | 
Nov 30, 2018
 |  BC Week In Review  |  Company News  |  Sales & Marketing

NICE recommends Keytruda combo in first-line NSCLC

U.K.’s NICE recommended in draft guidance anti-PD-1 mAb Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) for use in combination with chemotherapy through the Cancer Drug Fund for untreated, metastatic non-squamous non-small cell lung cancer. Consistent...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >